FAM
TCRR

Formidable Asset Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Formidable Asset Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,733
Closed -$540K – 289
2019
Q4 		$540K Buy
+4,733
New +$73.2K 0.17% 115

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Formidable Asset Management's TCRR Position: Q1 2020 in Review

Formidable Asset Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2020, closing a stake of 4,733 shares — an estimated $540K sold.

Formidable Asset Management first reported a position in TCRR in Q4 2019 and held it in 1 quarter. The position peaked at $540K in Q4 2019. 50 funds tracked by Wall St. Rank hold TCRR as of Q1 2020.

  • Formidable Asset Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Formidable Asset Management sold 4,733 TCR2 Therapeutics Inc. Common Stock shares in Q1 2020, an estimated $540K.
  • Formidable Asset Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Formidable Asset Management's TCR2 Therapeutics Inc. Common Stock position peaked at $540K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2020.

Based on Formidable Asset Management's 13F filing for Q1 2020, filed 1 Jun 2020.